Neurocrine Biosciences | Pre Utilidad Fiscal



Pre Tax Profit Cambio Fecha
AbbVie USD 4.81B 1.54B 2024-12
Acadia Pharmaceuticals USD 161.08M 122.28M 2024-12
Agios Pharmaceuticals USD -105399000 1.11B 2024-12
ALKERMES USD 443.75M 333.52M 2024-12
Alnylam Pharmaceuticals USD -193958000 85.3M 2024-12
Amgen USD 3.38B 111M 2024-12
Biogen USD 572.2M 118.5M 2024-12
BioMarin Pharmaceutical USD 169.64M 35.2M 2024-12
Cytokinetics USD -150020000 10.52M 2024-12
Dynavax Technologies USD 7.63M 12.19M 2024-12
Exelixis USD 184.77M 30.02M 2024-12
Gilead Sciences USD 2.96B 112M 2024-12
Halozyme Therapeutics USD 557.13M 359.8M 2024-12
Incyte USD 406.83M 147.12M 2024-12
Ionis Pharmaceuticals USD -107000000 37M 2024-12
Neurocrine Biosciences USD 162.6M 27.7M 2024-12
Pfizer USD 4.44B 2.36B 2024-12
Prothena USD -59501000 335K 2024-12
Regeneron Pharmaceuticals USD 958.1M 534.9M 2024-12
Repligen USD 30.77M 7.87M 2024-09
Sarepta Therapeutics USD 171.74M 137.74M 2024-12
Teva Pharmaceutical Industries USD 899M 1.22B 2024-12
Ultragenyx Pharmaceutical USD -133404000 191K 2024-12
Vertex Pharmaceuticals USD 1.32B 109.7M 2024-12



Neurocrine Biosciences Pre Utilidad Fiscal - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Apr 2025.